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AbsTrACT
background genome-wide association studies have 
identified >30 common SnPs associated with epithelial 
ovarian cancer (eOc). We evaluated the combined effects 
of eOc susceptibility SnPs on predicting eOc risk in an 
independent prospective cohort study.
Methods We genotyped ovarian cancer susceptibility 
single nucleotide polymorphisms (SnPs) in a nested 
case–control study (750 cases and 1428 controls) from 
the UK collaborative trial of Ovarian cancer Screening 
trial. Polygenic risk scores (PrSs) were constructed and 
their associations with eOc risk were evaluated using 
logistic regression. the absolute risk of developing 
ovarian cancer by PrS percentiles was calculated.
results the association between serous PrS and serous 
eOc (Or 1.43, 95% ci 1.29 to 1.58, p=1.3×10–11) 
was stronger than the association between overall PrS 
and overall eOc risk (Or 1.32, 95% ci 1.21 to 1.45, 
p=5.4×10–10). Women in the top fifth percentile of the 
PrS had a 3.4-fold increased eOc risk compared with 
women in the bottom 5% of the PrS, with the absolute 
eOc risk by age 80 being 2.9% and 0.9%, respectively, 
for the two groups of women in the population.
Conclusion PrSs can be used to predict future risk 
of developing ovarian cancer for women in the general 
population. incorporation of PrSs into risk prediction 
models for eOc could inform clinical decision-making 
and health management.
InTroduCTIon
Ovarian cancer (OC) is the sixth most common 
cancer in women with 7378 women diagnosed with 
the cancer in the UK in 2014. Epithelial ovarian 
cancer (EOC) is the most common type, accounting 
for 90% of OC, of which two-thirds are serous 
EOC.1 The overall 10-year survival rate for OC is 
around 36% and is poorer when diagnosed at an 
advance stage.2 Therefore, early diagnosis has the 
potential to improve survival rates; however, most 
women with symptoms present with advanced 
stage disease. Epidemiological studies have esti-
mated the risk of OC in first-degree relatives of 
patients with OC to be threefold greater than the 
risk in the general population, indicating the impor-
tance of genetic factors in disease susceptibility.3 
High penetrance mutations in BRCA1 and BRCA2 
explain around 25% of the observed familial rela-
tive risk (FRR)3 and a further 10% is explained by 
moderate-risk mutations in MLH1, MSH2, MSH6, 
RAD51C, RAD51D and BRIP1.4 Genome-wide 
association studies (GWAS) have identified ~30 
common low-risk SNPs that are associated with 
EOC, accounting for approximately 6.4% of the 
FRR.5 6 Additional potential susceptibility loci were 
identified by pleiotropy cancer GWAS analysis.7 
Although individually each SNP is associated with a 
low risk of EOC, in combination their effects on risk 
may be greater. Their inclusion in EOC risk predic-
tion models may improve risk precision.3 Providing 
refined personalised cancer risks can result in better 
risk stratification and hence help in improving early 
cancer detection and prevention.
Previous published studies investigating the 
combined effects of EOC SNPs in terms of poly-
genic risk scores (PRSs) have either been based 
on retrospective studies or overlapped with the 
association studies that led to the identification 
of the SNPs. Here, we use data from an indepen-
dent prospective population-based cohort study, 
the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS), to evaluate the EOC PRSs 
in predicting EOC risk prospectively.
MeThods
study subjects
UKCTOCS is a randomised controlled trial for 
OC screening initiated in 2001. Postmenopausal 
women between age 50 and 74 years were recruited 
from 13 regional centres in National Health Service 
(NHS) Trusts in England, Wales and Northern 
Ireland.8 9 Exclusion criteria included self-reported 
previous bilateral oophorectomy or ovarian malig-
nancy, increased risk of OC due to history of OC 
or breast cancer in the family or known OC predis-
posing mutations, or had an active non-ovarian 
malignancy.8–10 All participants provided written 
informed consent. All women completed a 
two-page 18-item baseline questionnaire at recruit-
ment which captured data on the known OC risk 
factors (eg, personal/family cancer history, height/
weight, reproductive history, oral contraceptive pill 
(OCP) and hormone replacement therapy use).9 
Two postal follow-up questionnaires were sent to 
the women, with the first 3–5 years post-randomis-
ation and the second in 2014.8 A blood sample was 
donated by each woman at recruitment and serum 
was extracted as previously described.9 Further 
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details on sample processing and DNA extraction are provided 
in the online supplementary material. Notification of cancer 
diagnosis and deaths were through NHS Digital for the women 
residing in England and the Northern Ireland Cancer Registry 
and Central Services Agency for those residing in Northern 
Ireland. For women who developed OC, medical notes were 
retrieved and independently reviewed by an Outcomes Review 
Committee who assigned histological subtype, stage and grade. 
For the present study, we used a nested case–control design in 
women of self-reported white European ancestry. Cases were 
defined as women diagnosed with incident invasive epithelial 
ovarian or fallopian tube cancers or primary peritoneal cancer. 
Two random controls were selected per case, matched on 
regional centre, age at randomisation and year at recruitment. 
Following an outcomes review on 31 December 2014,8 a total of 
750 EOC cases and 1428 controls were included in the present 
analysis.
snP selection and genotyping
A panel of 96 SNPs were designed on the basis of their associ-
ation with EOC risk from the meta-analysis of Kuchenbaecker 
et al5 (online supplementary figure 1). These included SNPs 
from 50 regions that demonstrated associations at genome-wide 
significance level but also regions with associations at p<10−5. 
This was done in view of the ongoing OncoArray experiment6 
that was being performed on a larger sample size compared 
with the study of Kuchenbaecker et al. For each region, multiple 
correlated SNPs were selected for inclusion in the panel to ensure 
data availability in case of SNP genotyping failures.
Genotyping was performed on 96.96 dynamic arrays using the 
Fluidigm EP1 system (Fluidigm, San Francisco, California, USA) 
from 10 ng of DNA following the manufacturer’s conditions 
using the pre-amplification protocol. The 96 SNPs included 
inventoried and Custom Assay-by-Design TaqMan probes 
(Applied Biosystems). Analysis was performed using Genotyping 
SNP Analysis software (Fluidigm). In total, 52 SNPs failed 
quality control (QC) due to poor clustering on the serum DNA 
samples, leaving 44 SNPs for analysis. To ensure consistency with 
the most recent GWAS results, SNPs were selected for inclusion 
in the PRS if they were in regions that showed genome-wide 
significance in the OncoArray experiment6 (online supplemen-
tary figure 1). Of the 44 SNPs, 19 SNPs were from 15 genome-
wide significant regions reported in the OncoArray experiment 
(online supplementary figure 1). In total, 191 samples with call 
rates <80% were excluded (8%); therefore, 2178 samples passed 
QC (750 cases and 1428 controls). Any 96-well plates with 
pass rates <80% were excluded for a particular SNP. Also, 131 
duplicate samples were included, and the concordance for dupli-
cate samples was 97.6%. SNPs with significant deviations from 
Hardy-Weinberg equilibrium were assessed for quality of geno-
type clustering. All demonstrated clear clusters of genotyping 
calls and were therefore included in the analysis.
snP selection for inclusion in the Prs
The selection of genotyped SNPs for inclusion in the PRS was 
based on the latest results from the meta-analysis of GWAS for 
EOC reported by Phelan et al.6
Two separate PRS were constructed: one for overall EOC and 
one for serous EOC. The overall PRS was constructed using the 
set of SNPs that showed associations with overall or any type of 
EOC at GWAS level. The serous PRS was constructed using the 
set of SNPs that showed associations with overall or any type of 
EOC at GWAS level, but also showed associations in the same 
direction for serous EOC. Only one SNP from each region was 
used. For each region, if the most significant SNP in the GWAS 
was among the SNPs genotyped, then it was selected for inclu-
sion in the PRS. If the top SNP was not available, then we used 
a genotyped SNP (among the 44) from the region which had 
the highest correlation with the top published SNP. In total, 15 
SNPs from 15 regions were included in the overall PRS construc-
tion and the same set of SNPs was selected for the serous PRS 
construction.
statistical analysis
To construct the PRS, we first evaluated all pairwise SNP inter-
actions among the SNPs included in the PRS for their associ-
ations with EOC risk using logistic regression. In each model, 
the effects of both SNPs were included (as continuous variables 
taking values 0, 1 and 2) together with an interaction term 
between the SNPs. The quantile–quantile plot (qqplot) for all 
pairwise combinations were examined for the null hypothesis 
of no interaction effect. A Bonferroni correction was applied to 
adjust for multiple testing. The adjusted p value threshold was 
set at 8.3×10−5.
The PRS for individual i was defined as
  PRSi = β1g1i + β2g2i + ...βkgki... + βngni  (1)
where gki is the number of effect alleles for SNP k in individual 
i (taking values 0, 1 and 2) and βk is the per-allele log odds ratio 
(OR) for developing EOC associated with each copy of the effect 
allele of SNP k and n is the total number of SNPs used (n=15, 
online supplementary table 1). The log OR estimates for each 
SNP were obtained from the combined COGS and OncoArray 
association analyses of the Ovarian Cancer Association Consor-
tium6 (online supplementary table 1). For the overall PRS, we 
used the log OR estimates for developing overall EOC; for the 
serous PRS, we used the log OR estimates for serous EOC. For 
women with missing SNP genotypes (due to genotyping fail-
ures), we used the mean genotypes in controls and cases for each 
SNP separately.
Logistic regression was used to examine the association 
between the PRS and outcome. When investigating the overall 
PRS, the outcome (cases) was all invasive EOC (any histotype). 
When investigating the PRS for serous EOC, the outcome was 
serous EOC only. In each case, the PRS was treated as either a 
continuous or a categorical variable. The PRS was standardised 
by subtracting the mean in controls and dividing by the standard 
deviation (SD) in controls. When used as a categorical predictor, 
the PRS was grouped into the percentiles: [0,5%), [5%,10%), 
[10%,20%), [20%,40%), [40%,60%), [60%,80%), [80%,90%), 
[90%,95%) and [95%,100%] on the basis of the PRS distribu-
tion in controls with [0,5%) as the lowest 5% PRS group and 
[95%,100%] as the highest. The middle [40%,60%) group 
was used as the reference category. The observed ORs by PRS 
percentiles were compared with the theoretical OR predictions 
under a multiplicative polygenic model of inheritance.11
Additional analyses were performed by adjusting for age 
and family history of EOC. Age was considered to be the age 
at EOC diagnosis for cases and at the age at last follow-up or 
age at the first non-EOC cancer (whichever occurred first) for 
controls. Two separate family history variables were constructed 
indicating (1) the number of relatives diagnosed with EOC in 
first-degree relatives and (2) indicating the number of affected 
relatives in both first-degree and second-degree relatives. We 
performed separate analyses adjusting for each of the two family 
history variables. Family history information was available at 
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the baseline questionnaire. The discriminatory power of the 
PRS was assessed by the C-statistic using R package ‘pROC’. All 
statistical tests were two-tailed, and the significance threshold 
was set at 0.05.
The age-specific absolute risks of developing EOC by PRS 
percentiles were calculated by considering the OC incidence by 
PRS percentile and competing causes of mortality (other than 
EOC). We used data on EOC incidences and mortality rates 
were from the UK during 2012–2014.1 12 The OC risks by PRS 
percentiles were calculated as
 
 
RiskPRS
(
t
)
=
t∑
u=0
λPRS
(
u
) · SPRS (u) · Sm (u)
 
 (2)
where  λPRS
(
t
)
  is the OC incidence associated with PRS at 
age t,  SPRS
(
t
)
  is the PRS-specific survival function of being OC 
free at age t and  Sm
(
t
)
  is the survival function at age t calcu-
lated on the basis of incidences of death from causes other than 
OC. To calculate the OC incidence for each PRS percentile, we 
assumed that the average, age-specific OC incidences, over all 
PRS percentiles, agreed with the population OC incidences and 
calculated the PRS-specific incidence recursively. Details of these 
methods have been described elsewhere.11 13 14
resulTs
Data on 1428 controls and 750 EOC cases were included 
in the overall PRS analysis. Data on the same 1428 controls 
and 489 serous EOC cases (including 417 high-grade serous) 
were included in the serous PRS association analysis. Table 1 
summarises the study characteristics and provides a breakdown 
by histology subtype. A summary of the SNPs included the PRS 
is shown in online supplementary table 1.
Pairwise snP*snP interaction analysis
A total of 105 pairwise SNP*SNP interaction tests were 
performed but there was no significant evidence of interaction 
between any SNP pairs after a Bonferroni adjustment. The plot 
of observed against expected −log10p values did not show a 
significant departure from the expected values under the null 
hypothesis of no interaction (figure 1).
Association between Prs and ovarian cancer
Figure 2A shows that the PRS follows a nearly normal distri-
bution in both controls and cases where the mean of cases was 
right shifted by 0.28 for the overall standardised PRS and 0.37 
for the serous standardised PRS. There was a significant asso-
ciation between the overall PRS and overall EOC in the nested 
case–control study and the association was stronger between the 
serous PRS and serous EOC. The OR per unit SD was estimated 
to be 1.32 (95% CI 1.21 to 1.45, p=5.38 × 10–10) for the overall 
PRS and 1.43 (95% CI 1.29 to 1.58, p=1.28 × 10–11) for the 
serous PRS (table 2).
The associations between the overall PRS and overall EOC, 
and between the serous PRS and serous EOC, stratified by age 
are shown in table 2. No significant interaction between age 
and EOC was observed in either the overall or the serous group 
(table 2). Discrimination as measured by the C-statistic was equal 
to 0.58 (95% CI 0.55 to 0.60) for the overall PRS and 0.60 (95% 
CI 0.57 to 0.63) for the serous PRS.
The estimated ORs by percentiles of PRS compared with the 
middle quintile ([40%,60%)) are shown in figure 2B. The ORs 
increased with increasing PRS percentiles for both the overall 
and the serous PRS. In the overall group, the OR for developing 
EOC for women in the lowest overall PRS percentile ([0,5%)) 
was estimated to be 0.53 (95% CI 0.30 to 0.89) and the OR for 
those in the highest overall PRS percentile ([95%,100%]) was 
1.77 (95% CI 1.20 to 2.61) compared with the women in the 
middle overall PRS quintile. In the serous group, the OR for 
developing serous EOC was estimated to be 0.51 (95% CI 0.25 
to 0.94) for women in the lowest serous PRS percentile ([0,5%)) 
and 2.16 (95% CI 1.40 to 3.30) for women in the highest serous 
PRS percentile ([95%,100%]) compared with the women in the 
middle serous PRS quintile (table 3). The family history of OC 
alone did not show significant association with EOC risk (OR 
for family history in first-degree relatives=1.51, 95% CI 0.94 to 
2.41; OR for family history in first-degree and second-degree 
relatives=1.32, 95% CI 0.90 to 1.91). After adjusting by family 
history of OC, the OR estimates of PRS percentiles remained 
Table 1 A summary of epidemiological characteristics of the subjects 
included in the nested case–control study
Controls Cases P_difference*
Women (n) 1428 750
Age at baseline (%) 0.70
  <60 496 (34.7%) 256 (34.1%)
  60–69 701 (49.1%) 381 (50.8%)
  ≥70 231 (16.2%) 113 (15.1%)
Age at censoring (%) <0.0001
  <60 50 (3.5%) 107 (14.3%)
  60–69 388 (27.2%) 354 (47.2%)
  70–79 681 (47.7%) 275 (36.7%)
  ≥80 309 (21.6%) 14 (1.9%)
birth cohort (%) 0.76
  <1930 28 (2.0%) 10 (1.3%)
  1930–1939 639 (44.7%) 339 (45.2%)
  1940–1949 669 (46.8%) 354 (47.2%)
  ≥1950 92 (6.4%) 47 (6.3%)
Mean age at baseline 
(sd)
63 (6.2) 63 (6.2)
Mean censored age (sd) 74 (7.1) 68 (6.6)
Mean Prs (sd)
  Overall −0.47 (0.27) −0.39 (0.27)
  Serous −0.55 (0.35) −0.43 (0.36)
Family history of ovarian 
cancer (%)
Considering only first-
degree relatives 
0.088
  Zero affected relatives 1387 (97.1%) 718 (95.7%) 
  One affected relative 41 (2.9%) 32 (4.3%)  
Considering both first-
degree and second- 
degree relatives 
0.15
  Zero affected relatives 1356 (95.0%) 701 (93.5%) 
  One or more affected 
relatives 
72 (5.0%) 49 (6.5%)  
Morphology/histotype 
(%)
Serous 489 (65.2%)
  High grade 417 (55.6%)
  Low grade 23 (3.1%)
  Missing 49 (6.5%)
Clear cell 29 (3.9%)
Endometrioid 56 (7.5%)
Mucinous 24 (3.2%)
Others 152 (20.3%)
*χ2 tests for differences in the distributions between cases and controls.
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similar (table 3) but there was some attenuation in the effect of 
family history in first-degree and second-degree relatives of 3% 
on the log-scale. The observed distribution of the OR estimates 
was in line with the ORs theoretical-predicted values under the 
assumption that all SNPs interact multiplicatively (figure 2B) 
with all 95% CI for the observed OR estimates containing the 
theoretical estimates.
Absolute risk of developing oC by Prs percentiles
Figure 3 shows the predicted age-specific absolute risk of devel-
oping overall EOC by different PRS percentile categories. By 
age 80, the risks of developing EOC for women in the highest 
and lowest 5% of the PRS are predicted to be 2.9% and 0.9%, 
respectively.
dIsCussIon
Prior to incorporating the effects of common genetic variants 
into risk prediction models, it is important to calibrate the 
magnitude of their associations in studies which are independent 
of the original GWAS. This is the first prospective cohort study 
to evaluate the combined effects of GWAS identified common 
SNPs on EOC risk. We used data from a cohort of women in 
which women with known strong family history of OC or with 
known high-risk mutations were excluded. Therefore, the results 
are more applicable to women at ‘low risk’ of developing OC. 
Figure 1 Quantile–quantile plot shows the observed against expected 
−log10p values of pairwise SnP*SnP interaction tests under the null 
hypothesis of multiplicative model. the dashed line shows the 95% 
concentration band.
Figure 2 (a) Distribution of the standardised overall and serous polygenic risk scores (PrSs) in overall and serous ovarian cancer cases and controls. the 
dashed vertical lines show the PrS means. (B) Or estimates between overall/serous PrS percentiles and overall/serous ovarian cancer risk relative to the 
middle PrS quintile (40%–60%). the solid line shows the estimated Ors with 95% ci, and the dashed line represents the theoretical Or values assuming 
multiplicative model.
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Our results show that SNPs combine multiplicatively on EOC 
risk and that the PRS predicts EOC risk prospectively. There 
was a stronger association with the serous EOC for predicting 
the risk of serous EOC. This was expected as most of the SNPs 
used in the PRS construction showed stronger associations with 
serous EOC in the published GWAS. The empirical OR estimates 
for EOC associated with different percentiles of the PRS were in 
line with the theoretical expected values under the multiplicative 
model, suggesting the PRS is calibrated at the extremes of the 
distribution, although the OR estimates are associated with wide 
CIs. There was 3.4-fold difference in the risk of EOC between 
women at the 5th and 95th percentiles of the PRS. However, the 
discriminatory ability of the ‘PRS alone’ is modest with an area 
under the receiver-operating characteristic curve of 0.58–0.60 
(based on 1428 controls, 750 overall OC cases, 489 serous OC 
cases).
There was no evidence of an interaction between the PRS 
and age in our study, suggesting that the relative effect of the 
PRS remains constant with age. Little changes were observed 
in the OR estimates associated with the PRS after adjusting for 
family history of OC (table 3). Overall, family history of OC 
was not significantly associated with EOC risk in the present 
study, but this could be a consequence of the study design. One 
of the eligibility criteria for inclusion in the UKCTOCS trial was 
that women had to be at low risk of familial OC; therefore, the 
overall cohort is ‘biased’ towards women without significant 
family history of OC. However, the reduction in the effect size 
for family history after adjusting for the PRS is consistent with 
the predicted contribution of the SNPs to the familial risk of OC. 
To assess the effect of family history on OC accurately and the 
possible attenuation in the family history association after taking 
into account the PRS, larger studies with more representative 
samples of women from the population (with respect to family 
history) would be required.
The current estimate of lifetime EOC risk in the UK general 
population is 1.86% based on 2014 data. Our results show that 
using the PRS alone results in a cumulative EOC risk by age 
80 of 2.92% for women in the highest 5% of the overall PRS 
percentiles and 0.88% for women in the lowest 5% of the PRS. 
Although such differences alone may not lead to changes in the 
clinical management of women (eg, use of risk-reducing treat-
ments such as salpingo-oophorectomy), the PRS in combination 
Table 2 Association between polygenic risk scores (PRS) and ovarian cancer in different age groups 
Age group
overall serous
or (95% CI) P values or (95% CI) P values
All ages 1.32 (1.21 to 1.45) 5.38×10–10 1.43 (1.29 to 1.58) 1.28×10–11
<60 1.29 (0.91 to 1.86) 0.16 1.46 (1.01 to 2.17) 0.05
60–69 1.28 (1.11 to 1.49) 8.99×10–4 1.34 (1.14 to 1.59) 4.51×10–4
≥70 1.36 (1.20 to 1.55) 3.02×10–6 1.47 (1.26 to 1.72) 7.10×10–7
Interaction 1.00 (0.99 to 1.02) 0.88 1.00 (0.98 to 1.02) 0.95
In the overall PRS analysis, we used cases of any type of ovarian cancers and in the serous PRS analysis we used cases of serous ovarian cancer. 
Table 3 Association between polygenic risk scores (PRS) percentiles and ovarian cancer risk: unadjusted and adjusted by family history of ovarian 
cancer (FH) in first-degree or in first-degree and second-degree relatives
Prs percentile 
category (%) Controls (n) Cases (n)
or (95% CI)
unadjusted by Fh Adjusted by first-degree Fh
Adjusted by first-degree and 
second-degree Fh
(a) Overall 
  [0,5) 72 20 0.53 (0.30 to 0.89) 0.53 (0.31 to 0.89) 0.54 (0.31 to 0.90)
  [5,10) 71 17 0.46 (0.25 to 0.79) 0.46 (0.25 to 0.79) 0.46 (0.25 to 0.79)
  [10,20) 143 47 0.63 (0.42 to 0.92) 0.63 (0.43 to 0.92) 0.63 (0.43 to 0.92)
  [20,40) 285 137 0.92 (0.69 to 1.22) 0.92 (0.70 to 1.23) 0.93 (0.70 to 1.23)
  [40,60) 286 150 1 1 1
  [60,80) 285 159 1.06 (0.81 to 1.40) 1.07 (0.81 to 1.42) 1.07 (0.81 to 1.41)
  [80,90) 143 102 1.36 (0.99 to 1.88) 1.37 (0.99 to 1.89) 1.37 (1.00 to 1.90)
  [90,95) 71 51 1.37 (0.91 to 2.06) 1.37 (0.91 to 2.06) 1.37 (0.90 to 2.06)
  [95,100] 72 67 1.77 (1.20 to 2.61) 1.79 (1.21 to 2.64) 1.78 (1.21 to 2.62)
  FH 1.52 (0.94 to 2.44) 1.28 (0.88 to 1.87)
(b) Serous
  [0,5) 72 12 0.51 (0.25 to 0.94) 0.51 (0.25 to 0.94) 0.51 (0.25 to 0.95)
  [5,10) 71 10 0.43 (0.20 to 0.83) 0.43 (0.20 to 0.82) 0.43 (0.20 to 0.83)
  [10,20) 141 33 0.71 (0.45 to 1.10) 0.72 (0.46 to 1.11) 0.72 (0.45 to 1.11)
  [20,40) 287 78 0.83 (0.59 to 1.16) 0.83 (0.59 to 1.17) 0.83 (0.59 to 1.17)
  [40,60) 286 94 1 1 1
  [60,80) 285 102 1.09 (0.79 to 1.51) 1.09 (0.79 to 1.51) 1.09 (0.79 to 1.51)
  [80,90) 143 68 1.45 (1.00 to 2.10) 1.45 (1.00 to 2.10) 1.45 (1.00 to 2.10)
  [90,95) 71 41 1.76 (1.12 to 2.75) 1.77 (1.13 to 2.77) 1.77 (1.12 to 2.77)
  [95,100] 72 51 2.16 (1.40 to 3.30) 2.15 (1.40 to 3.30) 2.14 (1.39 to 3.28)
  FH 1.54 (0.88 to 2.63) 1.36 (0.88 to 2.08)
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with other established risk factors for EOC such as family 
history, other known rare genetic susceptibility variants and 
epidemiological risk factors (eg, OCP use, parity, endometri-
osis, tubal ligation) is likely to improve EOC risk stratification 
and help stratify the women in different risk categories.3 15 16 
For example, under Jervis et al’s model,3 the risk of developing 
EOC by age 80 for a woman at the highest 5% of the observed 
PRS is 6.6% if she has a mother diagnosed with EOC at age 
50. Furthermore, by combining all risk factors together, it has 
been demonstrated that there is a gradient of lifetime risk in 
unselected populations which ranges from 0.35% to 8.78%.17 
Although the present study is limited by the inclusion of women 
with no significant family history of OC, the findings are relevant 
to tailoring screening efforts in the future. In addition, these PRS 
can result in clinically significant differences in risk when used 
in combination with mutations in moderate penetrance genes 
such as RAD51C, RAD51D and BRIP1.16 Hence, risk modelling 
incorporating a combination of PRS, other rare genetic suscep-
tibility variants, family history and epidemiological factors may 
enable population risk stratification to identify individuals who 
will benefit from targeted interventions. For example, risk-re-
ducing salpingo-oophorectomy has been suggested to be cost-ef-
fective at >4%–5% lifetime risk of OC.18 19 This may provide 
clinical utility for undertaking surgical prevention above these 
levels of risk. A change in guidelines to enable women at above 
these risk thresholds to benefit from surgical prevention has 
been advocated.20
The present study has also several limitations. Some of the 
study participants had been diagnosed with another cancer prior 
to their recruitment into the study. These women were included 
in the analysis (52 incident cases, 111 controls) in line with 
previous GWAS. After excluding the women with a history of 
cancer, the results remain similar and the conclusions were not 
influenced by these assumptions (online supplementary tables 
2–4 and supplementary figure 2–5). Although the UKCTOCS 
study was not included in the recent GWAS,6 since this is a 
national study, it is possible that some incidental overlaps may 
exist with samples included in the Phelan et al study,6 if study 
participants enrolled independently in other studies. On further 
investigation by the coordinating centre, 34 incident OC cases 
and 5 of the controls in the study were also included in one of 
the case–control studies included in Phelan et al.6 After excluding 
the overlapping individuals the results remained virtually iden-
tical (data not shown). Another limitation is that the majority of 
the women were eligible to participate in the UKCTOCS study 
if they did not have family history of OC. Therefore, we were 
not able to obtain an unbiased estimates of the effect of family 
history. In the present study, the OR estimate associated with 
family history of OC is substantially lower compared with studies 
of familial risks of OC,3 but this is expected under the present 
design. A possible further implication of the present study design 
(ie, women selected for no family history) is a possible atten-
uation of the effect of the PRS due to the fact that common 
variants are expected to be confounded with family history of 
OC. However, the OR estimates for different percentiles of the 
PRS were in line with those expected under a multiplicative 
model, suggesting that this is unlikely to result in a substantial 
bias in the PRS associations. We note that although the multi-
plicative model assumption is further supported by the fact that 
no SNP*SNP interactions were detected, the current study is 
underpowered to investigate pairwise interactions of modest 
effects (online supplementary table 5). Larger studies will have 
to investigate this. The sample size is also limited for assessing 
the associations of the PRS with different histotypes, other than 
serous EOC. Although GWAS have demonstrated associations 
between SNPs and other EOC histotypes, the number of endo-
metrioid, clear cell and mucinous cancers were too small and 
the PRS did not show evidence associations with these histo-
types (online supplementary table 6). Additionally, the latest 
GWAS has identified many more common SNPs (~30) associ-
ated with EOC which were estimated to account for 6.4% of 
the polygenic risk in the population.6 The 15 SNPs included in 
the PRS and evaluated in the present study explained only 3.4% 
of the polygenic risk. Therefore, further improvement could be 
achieved by incorporating these additional SNPs into the PRS or 
by constructing PRS which include both genomewide significant 
SNPs and SNPs with higher p values of association using penal-
ised regression models.21–23
In conclusion, this paper is the first evaluation of the associ-
ation of the PRS with EOC in a prospective general population 
cohort. It demonstrates that the PRS based on published SNP 
effect sizes is well calibrated and the PRS is a strong risk factor 
for EOC that contributes towards the discrimination of women 
who will develop EOC. It will be necessary to incorporate the 
PRS in comprehensive OC risk prediction models together with 
other risk factors for the disease and assess the improvement in 
risk prediction in prospective studies. Such comprehensive risk 
models will facilitate the clinical decision-making and health 
management for at-risk women and provide more personalised 
risk management.
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